Treating Acute Leukemias in the Asia Pacific Region
Emerging and Practical Concepts and Controversies in Leukemias
Overview
In recent years, progress in the understanding of acute leukemias has led to novel therapies that are rapidly changing treatment paradigms. Aptitude Health developed the Global Leukemia Academy to help physicians who treat acute leukemias bridge the gap between innovation and implementation for patient care.
Date and Location
May 15–16, 2021, Virtual Meeting
Meeting Content
View the slides and watch the video of Day 1
ALL Plenary Session
Faculty
Elias Jabbour, MD
MD Anderson Cancer Center, USA
Patrick A. Brown, MD
Johns Hopkins University School of Medicine, USA
Naval Daver, MD
MD Anderson Cancer Center (MDACC), Houston, TX
Eunice Wang, MD
Roswell Park Comprehensive Cancer Center, USA
José Maria Ribera, MD, PhD
Catalan Institute of Oncology, University Hospital Germans Trias i Pujol, Spain
Aaron Logan, MD, PhD
UCSF, Helen Diller Family Comprehensive Cancer Care, USA
Lia Gore, MD
University of Colorado, Anschutz Medical Campus, USA
|
Agenda |
This 2-day interactive virtual meeting with global experts will focus on the management of acute leukemias in adult, young adult, and pediatric patients in various countries within the Asia Pacific region. Day 1: Follow presentations, interact in panel discussions, and debate about novel approved therapies, evolving treatment paradigms, and other hot topics, including patient management during the COVID-19 pandemic. Day 2: Join the pediatric or adult breakout session to learn about treatment strategies for newly diagnosed and relapsed ALL patients and attend the patient case-based panel discussion about toxicity management. |
Day 1 – PLENARY SESSIONS Saturday, May 15, 2021
Chair: Elias Jabbour, MD
9.00 – 13.00 JST/UTC +9 (Japan Standard Time)
8.00 – 12.00 HKT/UTC +8 (Hong Kong Time)
| Japan Time (UTC +9) | Topic | Presenter |
| 9.00 – 9.10 | Welcome and meeting overview; introduction to the voting system | Elias Jabbour |
| 9.10 – 9.50 | Recent developments in acute leukemias | Elias Jabbour |
| 9.50 – 10.15 | Review of prognostic value of MRD in acute leukemias | Aaron Logan |
| 10.15 – 10.30 | Genetic variants in ALL – Ph+ and Ph-like | José Maria Ribera |
| 10.30 – 10.45 | AYA ALL patients – what is the current treatment approach for this diverse patient population? | Lia Gore |
| 10.45 – 10.55 | Break | |
| 10.55 – 11.10 | Bispecifics as post-reinduction therapy improve survival in high-risk first-relapse pediatric and AYA B-ALL | Patrick Brown |
| 11.10 – 11.35 | Therapeutic approaches in high-risk and older AML patients | Naval Daver |
| 11.35 – 12.20 | Leukemia board discussion • Regional challenges in times of COVID-19 – Shaun Fleming (20 min) • Case discussion – Bhavna Padhye (15 min) • Discussion (10 min) |
Moderator: Elias Jabbour All faculty |
| 12.20 – 12.50 | Debate on sequencing CD19-targeted approaches • Monoclonal antibodies and bispecifics first (10 min) • CAR T first (10 min) • Discussion and voting (10 min) |
Moderator: Aaron Logan Elias Jabbour José Maria Ribera |
| 12.50 – 13.00 | Session close | Elias Jabbour |
Day 2 – BREAKOUT: ADULT LEUKEMIA PATIENTS Sunday, May 16, 2021
Chair: Elias Jabbour, MD
11.00 – 14.30 JST/UTC +9 (Japan Standard Time)
10.00 – 13.30 HKT/UTC +8 (Hong Kong Time)
| Japan Time (UTC +9) | Topic | Presenter |
| 11.00 – 11.15 | Session open • Educational ARS questions for the audience |
Elias Jabbour |
| 11.15 – 11.35 | Optimizing first-line therapy in adult and older ALL – integration of immunotherapy into frontline regimens • Presentation (15 min) • Q&A (5 min) |
Aaron Logan |
| 11.35 – 11.55 | Current treatment options for relapsed ALL in adult and elderly patients (including COVID-19 and vaccination strategy) • Presentation (15 min) • Q&A (5 min) |
José Maria Ribera, MD |
| 11.55 – 12.30 | Case-based panel discussion: Management of long- and short-term toxicities and treatment selection in adult and elderly patients Panelists: Elias Jabbour, Aaron Logan, Local Experts |
Shaun Fleming |
| 12.30 – 12.45 | Break | |
| 12.45 – 13.05 | Personalized induction and maintenance approaches for AML • Presentation (15 min) • Q&A (5 min) |
Naval Daver |
| 13.05 – 13.25 | Optimizing management of relapsed/refractory AML • Presentation (15 min) • Q&A (5 min) |
Eunice Wang |
| 13.25 – 14.15 | Case-based panel discussion or questions to the panel on regional challenges in AML care | Case 1: Chyn Chua Case 2: Sun Loo |
| 14.15 – 14.30 | Session close • Educational ARS questions for the audience |
Elias Jabbour |
Day 2 – BREAKOUT: PEDIATRIC ALL PATIENTS Sunday, May 16, 2021
Chair: Patrick Brown
11.00 – 13.30 JST/UTC +9 (Japan Standard Time)
10.00 – 12.30 HKT/UTC +8 (Hong Kong Time)
| Japan Time (UTC +9) | Topic | Presenter |
| 11.00 – 11.15 | Session open • Educational ARS questions for the audience |
Patrick Brown |
| 11.15 – 11.35 | First-line treatment of pediatric ALL • Presentation (15 min) • Q&A (5 min) |
Bhavna Padhye |
| 11.35 – 11.55 | Current treatment options for relapsed ALL in children, including HSCT; COVID-19 considerations and vaccinations • Presentation (15 min) • Q&A (5 min) |
Michael Osborn |
| 11.55 – 12.15 | Bispecifics for pediatric ALL, focus on frontline therapy • Presentation (15 min) • Q&A (5 min) |
Patrick Brown |
| 12.15 – 12.45 | Case-based panel discussion: Management of long-and short-term toxicities and treatment selection in pediatric patients Panelists: All faculty |
Case 1: Bhavna Padhye (10 min) Case 2: Michael Osborn (10 min) Discussion (10 min) |
| 12.45 – 13.30 | Interactive Q&A and session close • Educational ARS questions for the audience |
Patrick Brown |
